Drug Information

Drug General Information
Drug ID
D0A3OF
Former ID
DCL000817
Drug Name
GMC-283
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Terminated [536463]
Company
Merck KGaA
Structure
Download
2D MOL

3D MOL
Formula
C19H18F3N3O4S
Canonical SMILES
CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)OS(=O)(=O)C(F)<br />(F)F
InChI
1S/C19H18F3N3O4S/c1-24-8-10-25(11-9-24)18-14-12-13(29-30(26,27)19(20,21)22)6-7-16(14)28-17-5-3-2-4-15(17)23-18/h2-7,12H,8-11H2,1H3
InChIKey
DQNCRNVCBHYBQP-UHFFFAOYSA-N
CAS Number
CAS 183140-98-9
PubChem Compound ID
10026300
PubChem Substance ID
15007887, 22454549, 44143375, 77347201, 103269928, 103970697, 127772519, 134339291, 135697561, 252159905
Target and Pathway
Target(s) D(1B) dopamine receptor Target Info Antagonist [536463]
5-hydroxytryptamine 2A receptor Target Info Antagonist [536463]
D(2) dopamine receptor Target Info Antagonist [536463]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Dopaminergic synapsehsa04020:Calcium signaling pathway
Gap junction
Serotonergic synapse
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Dopamine receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
G alpha (i) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
SIDS Susceptibility Pathways
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR downstream signaling
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
Genes and (Common) Pathways Underlying Drug Addiction
Nicotine Activity on Dopaminergic Neurons
References
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.
Ref 536463The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.